{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T22:01:13Z","timestamp":1781128873662,"version":"3.54.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Shenzhen Second People\u2019s Hospital Clinical Research Fund of Guangdong Province High-level Hospital Construction Project","award":["20213357018"],"award-info":[{"award-number":["20213357018"]}]},{"name":"Shenzhen Key Medical Discipline Construction Fund","award":["SZXK009"],"award-info":[{"award-number":["SZXK009"]}]},{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzhen","doi-asserted-by":"crossref","award":["SZSM202211013"],"award-info":[{"award-number":["SZSM202211013"]}],"id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-024-03796-4","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T19:02:32Z","timestamp":1729796552000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effects of immunosuppressive therapy on renal prognosis in primary membranous nephropathy"],"prefix":"10.1186","volume":"25","author":[{"given":"Wangyang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongli","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mijie","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengchun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meifang","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingqiao","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiwei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qijun","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,24]]},"reference":[{"issue":"4","key":"3796_CR1","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1053\/j.ajkd.2021.07.019","volume":"79","author":"Advances in Understanding of Pathogenesis and Treatment of Immune-Mediated Kidney Disease","year":"2022","unstructured":"Advances in Understanding of Pathogenesis and Treatment of Immune-Mediated Kidney Disease. A review. Am J Kidney Dis. 2022;79(4):582\u2013600. https:\/\/doi.org\/10.1053\/j.ajkd.2021.07.019","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"3796_CR2","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1053\/j.ajkd.2020.10.009","volume":"77","author":"L Alsharhan","year":"2021","unstructured":"Alsharhan L, Beck LH. Membranous nephropathy: Core Curriculum 2021. Am J Kidney Dis. 2021;77(3):440\u201353. https:\/\/doi.org\/10.1053\/j.ajkd.2020.10.009","journal-title":"Am J Kidney Dis"},{"key":"3796_CR3","doi-asserted-by":"publisher","first-page":"116923","DOI":"10.1016\/j.lfs.2019.116923","volume":"238","author":"R Motavalli","year":"2019","unstructured":"Motavalli R, Etemadi J, Kahroba H, Mehdizadeh A, Yousefi M. Immune system-mediated cellular and molecular mechanisms in idiopathic membranous nephropathy pathogenesis and possible therapeutic targets. Life Sci. 2019;238:116923. https:\/\/doi.org\/10.1016\/j.lfs.2019.116923","journal-title":"Life Sci"},{"issue":"1","key":"3796_CR4","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41467-023-36068-0","volume":"14","author":"L Seifert","year":"2023","unstructured":"Seifert L, Zahner G, Meyer-Schwesinger C, et al. The classical pathway triggers pathogenic complement activation in membranous nephropathy. Nat Commun. 2023;14(1):473. https:\/\/doi.org\/10.1038\/s41467-023-36068-0","journal-title":"Nat Commun"},{"issue":"8","key":"3796_CR5","doi-asserted-by":"publisher","first-page":"e104936","DOI":"10.1371\/journal.pone.0104936","volume":"9","author":"Y Du","year":"2014","unstructured":"Du Y, Li J, He F, et al. The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy: a meta-analysis. PLoS ONE. 2014;9(8):e104936. https:\/\/doi.org\/10.1371\/journal.pone.0104936","journal-title":"PLoS ONE"},{"issue":"2","key":"3796_CR6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s40620-022-01528-1","volume":"36","author":"M Allinovi","year":"2023","unstructured":"Allinovi M, Lugli G, Rossi F, et al. Accuracy of serum PLA2R antibody detected by indirect immunofluorescence in diagnosing biopsy-proven primary membranous nephropathy: a single-center experience and a systematic review of the literature. J Nephrol. 2023;36(2):281\u20133. https:\/\/doi.org\/10.1007\/s40620-022-01528-1","journal-title":"J Nephrol"},{"issue":"6","key":"3796_CR7","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1053\/j.ajkd.2021.06.012","volume":"78","author":"Multitarget Combination Immunosuppressive Therapy for Primary Membranous Nephropathy","year":"2021","unstructured":"Multitarget Combination Immunosuppressive Therapy for Primary Membranous Nephropathy. Am J Kidney Dis. 2021;78(6):774\u20136. https:\/\/doi.org\/10.1053\/j.ajkd.2021.06.012","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"3796_CR8","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2215\/CJN.11761116","volume":"12","author":"WG Couser","year":"2017","unstructured":"Couser WG. Primary Membranous Nephropathy. Clin J Am Soc Nephrol. 2017;12(6):983\u201397. https:\/\/doi.org\/10.2215\/CJN.11761116","journal-title":"Clin J Am Soc Nephrol"},{"issue":"24","key":"3796_CR9","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1056\/NEJM197912133012401","volume":"301","author":"Collaborative Study of the Adult Idiopathic Nephrotic Syndrome","year":"1979","unstructured":"Collaborative Study of the Adult Idiopathic Nephrotic Syndrome. A controlled study of short-term prednisone treatment in adults with membranous nephropathy. N Engl J Med. 1979;301(24):1301\u20136. https:\/\/doi.org\/10.1056\/NEJM197912133012401","journal-title":"N Engl J Med"},{"issue":"15","key":"3796_CR10","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1056\/NEJM198404123101503","volume":"310","author":"Z Ponticelli Claudio","year":"1984","unstructured":"Ponticelli Claudio Z, Pietro I, Enrico, et al. Controlled Trial of Methylprednisolone and Chlorambucil in Idiopathic Membranous Nephropathy. N Engl J Med. 1984;310(15):946\u201350. https:\/\/doi.org\/10.1056\/NEJM198404123101503","journal-title":"N Engl J Med"},{"issue":"1","key":"3796_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1056\/NEJM198901053200102","volume":"320","author":"C Ponticelli","year":"1989","unstructured":"Ponticelli C, Zucchelli P, Passerini P, et al. A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med. 1989;320(1):8\u201313. https:\/\/doi.org\/10.1056\/NEJM198901053200102","journal-title":"N Engl J Med"},{"issue":"3","key":"3796_CR12","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1681\/ASN.V93444","volume":"9","author":"C Ponticelli","year":"1998","unstructured":"Ponticelli C, Altieri P, Scolari F, et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol. 1998;9(3):444\u201350. https:\/\/doi.org\/10.1681\/ASN.V93444","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"3796_CR13","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJM199208273270904","volume":"327","author":"C Ponticelli","year":"1992","unstructured":"Ponticelli C, Zucchelli P, Passerini P, Cesana B. Methylprednisolone plus Chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian idiopathic membranous Nephropathy Treatment Study Group. N Engl J Med. 1992;327(9):599\u2013603. https:\/\/doi.org\/10.1056\/NEJM199208273270904","journal-title":"N Engl J Med"},{"issue":"2","key":"3796_CR14","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/kisup.2012.20","volume":"2","author":"Chapter 7","year":"2012","unstructured":"Chapter 7. Idiopathic membranous nephropathy. Kidney Int Supplements. 2012;2(2):186\u201397. https:\/\/doi.org\/10.1038\/kisup.2012.20","journal-title":"Kidney Int Supplements"},{"issue":"9","key":"3796_CR15","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nm.1857","volume":"14","author":"C Faul","year":"2008","unstructured":"Faul C, Donnelly M, Merscher-Gomez S, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med. 2008;14(9):931\u20138. https:\/\/doi.org\/10.1038\/nm.1857","journal-title":"Nat Med"},{"issue":"4","key":"3796_CR16","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/ki.1995.161","volume":"47","author":"DC Cattran","year":"1995","unstructured":"Cattran DC, Greenwood C, Ritchie S, et al. A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group. Kidney Int. 1995;47(4):1130\u20135. https:\/\/doi.org\/10.1038\/ki.1995.161","journal-title":"Kidney Int"},{"issue":"4","key":"3796_CR17","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1046\/j.1523-1755.2001.0590041484.x","volume":"59","author":"DC Cattran","year":"2001","unstructured":"Cattran DC, Appel GB, Hebert LA, et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int. 2001;59(4):1484\u201390. https:\/\/doi.org\/10.1046\/j.1523-1755.2001.0590041484.x","journal-title":"Kidney Int"},{"issue":"9","key":"3796_CR18","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/sj.ki.5002215","volume":"71","author":"M Praga","year":"2007","unstructured":"Praga M, Barrio V, Ju\u00e1rez GF, Lu\u00f1o J. Grupo Espa\u00f1ol De Estudio De La Nefropat\u00eda Membranosa. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int. 2007;71(9):924\u201330. https:\/\/doi.org\/10.1038\/sj.ki.5002215","journal-title":"Kidney Int"},{"issue":"3","key":"3796_CR19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/MAJ.0b013e3181ca3a7d","volume":"339","author":"M Chen","year":"2010","unstructured":"Chen M, Li H, Li XY, et al. Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial. Am J Med Sci. 2010;339(3):233\u20138. https:\/\/doi.org\/10.1097\/MAJ.0b013e3181ca3a7d","journal-title":"Am J Med Sci"},{"issue":"3","key":"3796_CR20","first-page":"293","volume":"68","author":"K Hassan","year":"2016","unstructured":"Hassan K, Kristal B. Improving long-term outcomes in idiopathic membranous nephropathy using a distinctive cyclosporine regimen. Minerva Urol Nefrol. 2016;68(3):293\u2013301.","journal-title":"Minerva Urol Nefrol"},{"issue":"6","key":"3796_CR21","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.2215\/CJN.08880813","volume":"9","author":"JAJG van den Brand","year":"2014","unstructured":"van den Brand JAJG, van Dijk PR, Hofstra JM, Wetzels JFM. Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2014;9(6):1066\u201373. https:\/\/doi.org\/10.2215\/CJN.08880813","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"3796_CR22","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.1093\/ndt\/gfm366","volume":"22","author":"J Ballarin","year":"2007","unstructured":"Ballarin J, Poveda R, Ara J, et al. Treatment of idiopathic membranous nephropathy with the combination of steroids, tacrolimus and mycophenolate mofetil: results of a pilot study. Nephrol Dial Transpl. 2007;22(11):3196\u2013201. https:\/\/doi.org\/10.1093\/ndt\/gfm366","journal-title":"Nephrol Dial Transpl"},{"issue":"9868","key":"3796_CR23","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S0140-6736(12)61566-9","volume":"381","author":"A Howman","year":"2013","unstructured":"Howman A, Chapman TL, Langdon MM, et al. Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet. 2013;381(9868):744\u201351. https:\/\/doi.org\/10.1016\/S0140-6736(12)61566-9","journal-title":"Lancet"},{"issue":"8","key":"3796_CR24","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1681\/ASN.2012020181","volume":"23","author":"P Ruggenenti","year":"2012","unstructured":"Ruggenenti P, Cravedi P, Chianca A, et al. Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol. 2012;23(8):1416\u201325. https:\/\/doi.org\/10.1681\/ASN.2012020181","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"3796_CR25","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.2215\/CJN.06041108","volume":"4","author":"A Segarra","year":"2009","unstructured":"Segarra A, Praga M, Ramos N, et al. Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. Clin J Am Soc Nephrol. 2009;4(6):1083\u20138. https:\/\/doi.org\/10.2215\/CJN.06041108","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"3796_CR26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/sj.ki.5002628","volume":"73","author":"FC Fervenza","year":"2008","unstructured":"Fervenza FC, Cosio FG, Erickson SB, et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int. 2008;73(1):117\u201325. https:\/\/doi.org\/10.1038\/sj.ki.5002628","journal-title":"Kidney Int"},{"issue":"1","key":"3796_CR27","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1681\/ASN.2016040449","volume":"28","author":"K Dahan","year":"2017","unstructured":"Dahan K, Debiec H, Plaisier E, et al. Rituximab for severe membranous nephropathy: a 6-Month Trial with Extended Follow-Up. J Am Soc Nephrol. 2017;28(1):348\u201358. https:\/\/doi.org\/10.1681\/ASN.2016040449","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"3796_CR28","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.kint.2020.10.014","volume":"99","author":"G Fern\u00e1ndez-Ju\u00e1rez","year":"2021","unstructured":"Fern\u00e1ndez-Ju\u00e1rez G, Rojas-Rivera J, Logt AE, van de, et al. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int. 2021;99(4):986\u201398. https:\/\/doi.org\/10.1016\/j.kint.2020.10.014","journal-title":"Kidney Int"},{"issue":"6","key":"3796_CR29","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1213\/ANE.0000000000005773","volume":"133","author":"P Schober","year":"2021","unstructured":"Schober P, Mascha EJ, Vetter TR. Statistics from A (agreement) to Z (z score): a Guide to Interpreting Common Measures of Association, Agreement, Diagnostic Accuracy, Effect size, heterogeneity, and reliability in Medical Research. Anesth Analg. 2021;133(6):1633\u201341. https:\/\/doi.org\/10.1213\/ANE.0000000000005773","journal-title":"Anesth Analg"},{"key":"3796_CR30","doi-asserted-by":"publisher","unstructured":"B DG AT. Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy. Kidney Int. 2002;61(1). https:\/\/doi.org\/10.1046\/j.1523-1755.2002.00124.x","DOI":"10.1046\/j.1523-1755.2002.00124.x"},{"issue":"1","key":"3796_CR31","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa1814427","volume":"381","author":"FC Fervenza","year":"2019","unstructured":"Fervenza FC, Appel GB, Barbour SJ, et al. Rituximab or Cyclosporine in the treatment of Membranous Nephropathy. N Engl J Med. 2019;381(1):36\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1814427","journal-title":"N Engl J Med"},{"issue":"3","key":"3796_CR32","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ekir.2019.12.006","volume":"5","author":"N Hanset","year":"2020","unstructured":"Hanset N, Esteve E, Plaisier E, et al. Rituximab in patients with phospholipase A2 receptor\u2013Associated Membranous Nephropathy and severe CKD. Kidney Int Rep. 2020;5(3):331. https:\/\/doi.org\/10.1016\/j.ekir.2019.12.006","journal-title":"Kidney Int Rep"},{"issue":"6","key":"3796_CR33","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s40265-023-01855-y","volume":"83","author":"L Deng","year":"2023","unstructured":"Deng L, Xu G. Update on the application of monoclonal antibody therapy in primary Membranous Nephropathy. Drugs. 2023;83(6):507\u201330. https:\/\/doi.org\/10.1007\/s40265-023-01855-y","journal-title":"Drugs"},{"key":"3796_CR34","doi-asserted-by":"publisher","unstructured":"K C, W B, C C, B O. Systematic review of Safety and Efficacy of Second- and third-generation CD20-Targeting Biologics in Treating Immune-mediated disorders. Front Immunol. 2022;12. https:\/\/doi.org\/10.3389\/fimmu.2021.788830","DOI":"10.3389\/fimmu.2021.788830"},{"key":"3796_CR35","doi-asserted-by":"publisher","unstructured":"L B, S S, W Q, et al. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Cancer Res. 2008;68(7). https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-6663","DOI":"10.1158\/0008-5472.CAN-07-6663"},{"key":"3796_CR36","doi-asserted-by":"publisher","unstructured":"T R, E R. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs: Clin Immunotherapeutics Biopharmaceuticals gene Therapy. 2011;25(1). https:\/\/doi.org\/10.2165\/11539590-000000000-00000","DOI":"10.2165\/11539590-000000000-00000"},{"issue":"4","key":"3796_CR37","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.ekir.2021.01.022","volume":"6","author":"M Teisseyre","year":"2021","unstructured":"Teisseyre M, Boyer-Suavet S, Cr\u00e9moni M, Brglez V, Esnault V, Seitz-Polski B. Analysis and management of Rituximab Resistance in PLA2R1-Associated Membranous Nephropathy. Kidney Int Rep. 2021;6(4):1183\u20138. https:\/\/doi.org\/10.1016\/j.ekir.2021.01.022","journal-title":"Kidney Int Rep"},{"issue":"6","key":"3796_CR38","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1053\/j.ajkd.2020.02.444","volume":"76","author":"N Klomjit","year":"2020","unstructured":"Klomjit N, Fervenza FC, Zand L. Successful treatment of patients with refractory PLA2R-Associated Membranous Nephropathy with Obinutuzumab: a report of 3 cases. Am J Kidney Dis. 2020;76(6):883\u20138. https:\/\/doi.org\/10.1053\/j.ajkd.2020.02.444","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"3796_CR39","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.ekir.2020.06.030","volume":"5","author":"S Sethi","year":"2020","unstructured":"Sethi S, Kumar S, Lim K, Jordan SC. Obinutuzumab is effective for the treatment of Refractory Membranous Nephropathy. Kidney Int Rep. 2020;5(9):1515\u20138. https:\/\/doi.org\/10.1016\/j.ekir.2020.06.030","journal-title":"Kidney Int Rep"},{"issue":"3","key":"3796_CR40","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1053\/j.ajkd.2023.08.010","volume":"83","author":"MA Podest\u00e0","year":"2024","unstructured":"Podest\u00e0 MA, Trillini M, Portalupi V, et al. Ofatumumab in Rituximab-resistant and Rituximab-intolerant patients with primary membranous nephropathy: a Case Series. Am J Kidney Dis. 2024;83(3):340\u2013e3491. https:\/\/doi.org\/10.1053\/j.ajkd.2023.08.010","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"3796_CR41","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s00467-020-04481-y","volume":"35","author":"P Ravani","year":"2020","unstructured":"Ravani P, Pisani I, Bodria M, Caridi G, Degl\u2019Innocenti ML, Ghiggeri GM. Low-dose ofatumumab for multidrug-resistant nephrotic syndrome in children: a randomized placebo-controlled trial. Pediatr Nephrol. 2020;35(6):997\u20131003. https:\/\/doi.org\/10.1007\/s00467-020-04481-y","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"3796_CR42","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s00467-020-04811-0","volume":"36","author":"C Dossier","year":"2021","unstructured":"Dossier C, Prim B, Moreau C, et al. A global antiB cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome. Pediatr Nephrol. 2021;36(5):1175\u201382. https:\/\/doi.org\/10.1007\/s00467-020-04811-0","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"3796_CR43","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1053\/j.ajkd.2021.04.014","volume":"78","author":"Combination of Rituximab","year":"2021","unstructured":"Combination of Rituximab. Low-dose cyclophosphamide, and Prednisone for primary membranous nephropathy: a Case Series with Extended follow up. Am J Kidney Dis. 2021;78(6):793\u2013803. https:\/\/doi.org\/10.1053\/j.ajkd.2021.04.014","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"3796_CR44","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/ndt\/gfad156","volume":"39","author":"Y Duan","year":"2023","unstructured":"Duan Y, Bai Y, Guo W, et al. Multitarget therapy with a corticosteroid, cyclosporine and mycophenolate mofetil for idiopathic membranous nephropathy: a prospective randomized controlled trial. Nephrol Dial Transpl. 2023;39(1):95\u2013102. https:\/\/doi.org\/10.1093\/ndt\/gfad156","journal-title":"Nephrol Dial Transpl"},{"issue":"6","key":"3796_CR45","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/nep.13852","volume":"26","author":"K Karasawa","year":"2021","unstructured":"Karasawa K, Nakakita T, Miyabe Y, et al. Long-term therapeutic effects of multi-target therapy in a patient with membranous lupus nephritis: an interesting repeat kidney biopsy case. Nephrol (Carlton). 2021;26(6):562\u20133. https:\/\/doi.org\/10.1111\/nep.13852","journal-title":"Nephrol (Carlton)"},{"issue":"21","key":"3796_CR46","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.2169\/internalmedicine.1023-22","volume":"62","author":"Y Furuto","year":"2023","unstructured":"Furuto Y, Hashimoto H, Namikawa A, Morikawa T, Shibuya Y. Remission induction of IgG4-related Membranous Nephropathy with Multitarget Therapy. Intern Med. 2023;62(21):3175\u201381. https:\/\/doi.org\/10.2169\/internalmedicine.1023-22","journal-title":"Intern Med"},{"issue":"4","key":"3796_CR47","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1053\/j.ajkd.2008.04.013","volume":"52","author":"B Dussol","year":"2008","unstructured":"Dussol B, Morange S, Burtey S, et al. Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial. Am J Kidney Dis. 2008;52(4):699\u2013705. https:\/\/doi.org\/10.1053\/j.ajkd.2008.04.013","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"3796_CR48","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1093\/ndt\/gfm538","volume":"23","author":"L Senthil Nayagam","year":"2008","unstructured":"Senthil Nayagam L, Ganguli A, Rathi M, et al. Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study. Nephrol Dial Transpl. 2008;23(6):1926\u201330. https:\/\/doi.org\/10.1093\/ndt\/gfm538","journal-title":"Nephrol Dial Transpl"},{"issue":"6","key":"3796_CR49","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/j.1440-1797.2007.00822.x","volume":"12","author":"TM Chan","year":"2007","unstructured":"Chan TM, Lin AW, Tang SC, et al. Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome. Nephrol (Carlton). 2007;12(6):576\u201381. https:\/\/doi.org\/10.1111\/j.1440-1797.2007.00822.x","journal-title":"Nephrol (Carlton)"},{"issue":"2","key":"3796_CR50","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1053\/j.ajkd.2007.05.015","volume":"50","author":"AJ Branten","year":"2007","unstructured":"Branten AJ, du Buf-Vereijken PW, Vervloet M, Wetzels JF. Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide. Am J Kidney Dis. 2007;50(2):248\u201356. https:\/\/doi.org\/10.1053\/j.ajkd.2007.05.015","journal-title":"Am J Kidney Dis"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-024-03796-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-024-03796-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-024-03796-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T19:02:48Z","timestamp":1729796568000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-024-03796-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,24]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3796"],"URL":"https:\/\/doi.org\/10.1186\/s12882-024-03796-4","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,24]]},"assertion":[{"value":"16 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Medical Ethics Committee of Shenzhen Second People\u2019s Hospital (ethical number: 201408186) and Hechi People\u2019s Hospital (ethical number: 2020022). Since the patient data collected for this study was retrospective and had been anonymized and de-identified, informed consent forms were not required. Clinical trial number: not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"<b>Not applicable.<\/b>","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"377"}}